S
Sharadah Essapen
Researcher at Royal Surrey County Hospital
Publications - 36
Citations - 4433
Sharadah Essapen is an academic researcher from Royal Surrey County Hospital. The author has contributed to research in topics: Colorectal cancer & Cetuximab. The author has an hindex of 19, co-authored 35 publications receiving 3602 citations. Previous affiliations of Sharadah Essapen include Kingston University.
Papers
More filters
Journal ArticleDOI
A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J. Perren,Ann Marie Swart,Jacobus Pfisterer,Jonathan A. Ledermann,Eric Pujade-Lauraine,Gunnar B. Kristensen,Mark S. Carey,Philip Beale,Andrés Cervantes,Christian Kurzeder,Andreas du Bois,Jalid Sehouli,Rainer Kimmig,A. Stähle,Fiona Collinson,Sharadah Essapen,Charlie Gourley,Alain Lortholary,Frédéric Selle,Mansoor Raza Mirza,Arto Leminen,Marie Plante,Dan Stark,Wendi Qian,Wendi Qian,Mahesh K. B. Parmar,Amit M. Oza,Icon investigators +27 more
TL;DR: In patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months, higher than the average for women with ovarian cancer.
Journal ArticleDOI
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
Sean Kehoe,Jane Hook,Matthew Nankivell,Gordon C Jayson,Henry C Kitchener,Tito Lopes,David Luesley,Timothy J. Perren,Selina Bannoo,Monica Mascarenhas,Stephen Dobbs,Sharadah Essapen,Jeremy Twigg,Jonathan Herod,Glenn McCluggage,Mahesh K.B. Parmar,Ann Marie Swart,Ann Marie Swart +17 more
TL;DR: In women with stage III or IV ovarian cancer, survival with primary chemotherapy is non-inferior to primary surgery, and giving primary chemotherapy before surgery is an acceptable standard of care for women with advanced ovarian cancer.
Journal ArticleDOI
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial
Roger D James,Rob Glynne-Jones,Helen Meadows,David Cunningham,Arthur Sun Myint,Mark P Saunders,Tim Maughan,Alec McDonald,Sharadah Essapen,Martin Leslie,Stephen Falk,Charles Wilson,Simon Gollins,Rubina Begum,Jonathan A. Ledermann,Latha Kadalayil,David Sebag-Montefiore +16 more
TL;DR: The results of this trial--the largest in anal cancer to date--show that fluorouracil and mitomycin with 50.4 Gy radiotherapy in 28 daily fractions should remain standard practice in the UK.
Journal ArticleDOI
Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
TL;DR: Controversial data and explanatory factors are discussed as well as future studies for the establishment of more reliable markers for response to therapy with EGFR inhibitors to spare those who will receive no benefit or a detrimental effect from such biological agents.
Journal ArticleDOI
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Timothy Iveson,Rachel Kerr,Mark P Saunders,Jim Cassidy,Niels Henrik Hollander,Josep Tabernero,Andrew Haydon,Bengt Glimelius,Andrea Harkin,Karen Allan,John McQueen,Claire Scudder,Kathleen A Boyd,Andrew Briggs,Andrew Briggs,Ashita Waterston,Louise C. Medley,Charles Wilson,Richard Ellis,Sharadah Essapen,A.S. Dhadda,Mark Harrison,Stephen Falk,Sherif Raouf,Charlotte Rees,Rene K Olesen,David Propper,John Bridgewater,Ashraf Azzabi,David Farrugia,Andrew Webb,David Cunningham,Tamas Hickish,Andrew Weaver,Simon Gollins,Harpreet Wasan,James Paul +36 more
TL;DR: 3 months of oxaliplatin-containing adjuvant chemotherapy was non-inferior to 6 months of the same therapy for patients with high-risk stage II and stage III colorectal cancer and was associated with reduced toxicity and improved quality of life.